RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer.

K, Nakagawa; E, Nadal; EB, Garon; M, Nishio; T, Seto; N, Yamamoto; K, Park; JY, Shih; L, Paz-Ares; B, Frimodt-Moller; AH, Zimmermann; S, Wijayawardana; C, Visseren-Grul; M, Reck

doi:10.1158/1078-0432.ccr-21-0273

Public

RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer.

Shared by NobleBlocks on Oct 1, 2021 • 12:00 AM UTC

Authors:

Nakagawa K

Nadal E

Garon EB

Abstract

<h4>Purpose</h4>In EGFR-mutated metastatic non-small cell lung cancer (NSCLC), outcomes from EGFR tyrosine kinase inhibitors have differed historically by mutation type present, with lower benefit reported in patients with ex21L858R versus ex19del mutations. We investigated if EGFR-activating mutati...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!